Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622286 | 0.87 | ALB (0.31) | ALDH1A1AKR1B1 | |
| SCHEMBL13857053 | 0.69 | LDHA (0.44) | ALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL1891221 | 0.66 | EPHX2 (0.43) | ALDH1A1HPGDSMN1; SMN2MAPTRAB9A | |
| SCHEMBL1144495 | 0.64 | ALB (0.31) | ALDH1A1HPGDSMN1; SMN2MAPTRAB9A | |
| SCHEMBL1144454 | 0.62 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL28199964 | 0.62 | HPGD (0.40) | ALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL12664506 | 0.61 | EPHX2 (0.43) | ALDH1A1HPGDSMN1; SMN2MAPTRAB9A | |
| SCHEMBL27985775 | 0.60 | ALDH1A1 (0.39) | ALDH1A1HPGDSMN1; SMN2MAPTRAB9A | |
| Gossypolone SCHEMBL29407306 | 0.59 | AKR1B1 (0.44) | ALDH1A1HPGDSMN1; SMN2MAPTRAB9A | |
| SCHEMBL18878423 | 0.59 | NPSR1 (0.49) | ALDH1A1HPGDSMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118377-A1 | APOGOSSYPOLONE AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118377-A1 | APOGOSSYPOLONE AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118377-A1 | APOGOSSYPOLONE AND THE USES THEREOF | BCL2, BAD, BAX | ALDH1A1 3558/4885HPGD 341/4885SMN1; SMN2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.